The disease burden of cancer is a resource drain on our healthcare system, and there is a massive need for new and lifesaving medical interventions. The term “theranostics” was coined to define an agent used for diagnosis via imaging followed by therapy, and it's fast becoming the norm in personalised medicine ... (Press release)
BGM Pharmaceuticals and the South African Nuclear Energy Corporation (NECSA) to bring a new theranostic called GluCAB to market. This will be a first for South Africa, the partnership signifies a breakthrough in cancer diagnosis & treatment ... (Press release)
Through technology and science BGM Pharmaceuticals, UCT and NECSA have developed a new theranostics to deal with cancer. This partnership will be to bring about a one-of-a-kind cancer diagnosis and treatment innovation ... (Press release)
“The initial investment of R600m in the development of the theranostic will ensure that clinical trials prove safety and efficacy in a sufficient number of human subjects. More investment will be required to conduct multi-centre and multi-country clinical trials and in so doing, elevate GluCAB to global blockbuster status,” says BGM Pharma.